Purpose: To determine the prognostic value of Fas receptor and Fas ligand (FasL) as apoptosis-related biomarkers in the context of chemoresponsiveness in breast cancer (BC) patients submitted to anthracycline-based adjuvant therapy.
INTRODUCTION
Although the risk of mortality for breast carcinoma (BC) has been declining in the Western world over the last decade (1) , given the systemic nature of the disease at the time of diagnosis, an aggressive adjuvant chemotherapy (CT) is often required for stage I-II patients also (2) . Anthracyclines (doxorubicin or the 4-epimer epirubicin), considered the most effective drugs in advanced carcinomas, have been now introduced in the adjuvant setting and clinical data indicated that the inclusion of anthracyclines in adjuvant CT regimens produces a small but statistically significant improvement in survival over non-anthracycline-containing regimens (2) . Unfortunately most patients will develop an acquired resistance during treatment and die of progressive disease (3) . For this reason several studies have been devoted to the development of preclinical models aimed at understanding the molecular mechanisms producing treatmentresistant tumors. It is now well known that chemotherapeutic agents, irrespective of their intracellular target, act primarily through induction of apoptosis in susceptible cancer cells (4) . Thus, the efficacy of anticancer treatments does not depend on the DNA damage or other damage they cause, but is also related to the cellular capability to detect and respond to such damage (5) . However, the precise molecular requirements that characterize the drug-induced cell death in tumor cells are not completely understood (4, 6) . Mitochondrial and cell-surface death receptor-mediated apoptosis are the two principal pathways leading to programmed cell death (7) . The mitochondrial pathway is thought to play a major role in the response to cancer treatments and is mediated by the bcl-2 protein family. In addition there is mounting evidence that cell surface receptor molecules of the tumor necrosis factor/nerve growth factor receptor/ligand family, such as Fas (CD95/APO-1) and Fas ligand (FasL; CD95L) molecules, studied mostly within the immune system (8) , play a pivotal role also in drug-induced apoptosis of both leukemia and solid tumor cells (9 -11) . Recent in vitro studies demonstrated that apoptosis in response to different cytotoxic drugs is mostly triggered, through an autocrine/paracrine mechanism, by an intact Fas system activation pathway resulting in a correct cleavage and activation of effector caspases such as caspase-3 (12) . Therefore, interference with the FasL/receptor interaction by antagonist antibodies to the receptor or deficient activation of the Fas system may significantly reduce sensitivity to drug-mediated apoptosis (9) . These findings may suggest that, also in a clinical setting, an intact Fas-FasL apoptotic pathway system might play a pivotal role in determining sensitivity or resistance of tumor cells to anthracyclines. We have recently shown that BC is frequently associated with the down-regulation of Fas and the up-regulation of FasL (13) , demonstrating that a Fas-negative/FasL-positive phenotype, is significantly related to BC progression, strongly influencing patient outcome. Nevertheless in BC patients, no information is available on the relationship between the Fas/FasL system and response to anthracycline-based adjuvant therapy.
The aim of our study was to determine the clinical significance of Fas and FasL as apoptosis-related biomarkers in the context of chemoresponsiveness. To this end, we examined, by immunohistochemical (IHC) methods, the Fas and FasL expression in a series of 167 stage I-II BC patients enrolled in a prospective clinical trial using the epirubicin plus cyclophosphamide combination in the adjuvant setting.
MATERIALS AND METHODS
Patients. The 167 stage I, IIa, and IIb BC patients included in this study were treated at the Regina Elena Cancer Institute between 1991 and 1993. They were drawn from a larger trial of adjuvant anthracycline-containing combination CT with high-dose epirubicin plus cyclophosphamide (14). This series included 138 invasive ductal carcinomas and 29 invasive lobular carcinomas. Among these, 53 were stage I, 73 stage IIa, and 41 stage IIb. Tumors were staged according to the Unione Internationale Contre le Cancer tumor-node-metastasis (TNM) system criteria and histologically classified according to the WHO. According to the St. Gallen Consensus Conference, premenopausal women with invasive BC larger than 1 cm, grading 2-3, independent of nodal and hormonal receptors status, and postmenopausal patients with the same characteristics, but with negative estrogen and progesterone receptors were submitted every 3 weeks for four cycles to the following treatment: epirubicin (Farmorubicina; Pharmacia, Milan, Italy) 120 mg per m 2 of body surface area and cyclophosphamide (Endoxan; Asta Medica, Milan, Italy) 600 mg i.v. on day 1. Eligibility requirements for enrollment in the study included modified radical mastectomy or breast-conserving surgery (quadrantectomy) within 6 weeks before the start of CT; no prior CT or radiotherapy; age Ͻ65 years; adequate bone marrow, liver and renal functions; a resting left ventricular fraction (LVEF) Ͼ45%; no other malignancies; and informed consent. For patients treated with quadrantectomy, a standardized irradiation protocol was administered after the end of CT.
No patients received hormonal maintenance therapy (14). Follow-up data were obtained from hospital charts and by corresponding with the referring physicians.
Antibodies and IHC. Immunoreactivity for Fas protein was detected by using affinity-purified polyclonal antibody (Pab) C-20 (Santa Cruz Biotechnology, Santa Cruz, CA) raised against a peptide corresponding to amino acids 316 -335, mapping at the COOH terminus of the Fas of human origin. IHC staining was carried out on 5-m-thick sections on silane (APES; Sigma, St. Louis, MO)-treated slides from routinely fixed paraffin-embedded blocks. The deparafinized and rehydrated sections were pretreated twice in a microwave oven at 750 W for 5 min in citrate buffer and were incubated for 60 min at room temperature with primary Pabs (2 g/ml) and Mabs (1:40 dilution). The reaction was visualized using a streptavidinbiotin immunoperoxidase system (LSAB 2 kit; Dakocytomation, Milan, Italy) and 3-amino-9-ethyl-carbazole solution (Dakocytomation) as chromogenic substrate. Sections were then slightly counterstained with Mayer hematoxylin and were mounted in aqueous mounting medium (Glycergel; Dakocytomation). Benign and malignant tumors displayed two kinds of immunoreactivity: (a) a well-detectable cell membrane staining prevalently accompanied by a granular cytoplasmic reactivity; (b) a diffuse cytoplasmic staining varying from moderate to strong. Cases with faint, uncertain cytoplasmic staining were regarded as negative. For the purpose of our study, Fas or FasL immunostaining was scored, independent of membrane or cytoplasmic staining localization, as follows: negative, no expression on tumor cells; heterogeneous expression, 10 -50% positive tumor cells; homogeneous expression, Ͼ50% positive tumor cells. Normal breast tissues or benign lesions adjacent to invasive carcinomas were also carefully examined. Sections without primary antibodies or incubated with antibodies adsorbed with the immunizing peptides at a concentration of 20 g/ml (FasLamino-terminal, amino acids 2-19, and Fas-COOH-terminal, amino acids 316 -335; Santa Cruz Biotechnology) served as negative controls. All of the immunostained slides were analyzed and scored independently by two investigators (M. M. and S. B.).
Estrogen and progesterone receptors were assayed immunohistochemically on formalin-fixed paraffin-embedded tumors with the use of commercially available antibodies (ER1D5 and 1A6; Immunotech, UCS, Rome, Italy). Tumors were defined positive for estrogen and progesterone receptors when 10% or more of the tumor cells showed unequivocal nuclear staining.
HER-2/neu protein expression was evaluated using both the mouse Mab 300G9 provided by the Immunology Laboratory of the Regina Elena Cancer Institute, Rome, Italy (16) and the Pab A0485 purchased from Dakocytomation. HER-2/neu was considered overexpressed only when at least 10% of the neoplastic cells displayed a distinct plasma membrane staining (ϩϩ/ϩϩϩ score). Statistical Analysis. Association between clinical and biopathological variables was evaluated using the 2 test. All of these parameters were treated as dichotomous or categorical variables and were described using the Pearson statistic. The disease-free survival (DFS) and overall survival (OS) curves were estimated by the Kaplan-Meier product-limit method; the log-rank test was used to assess differences between subgroups. Significance was defined at the P Ͻ 0.05 level. The relative risk and the confidence limits were estimated for each variable by using the Cox univariate model and by adopting the most suitable prognostic category as referent group. A multivariate Cox proportional hazard model was also developed using stepwise regression (backward selection) with predictive variables that were significant in the univariate analyses. Enter limit and remove limit were P ϭ 0.10 and P ϭ 0.15, respectively. All of the analyses were conducted using the BMDP software package (Chicago, IL).
Coexpression of Fas and FasL was also analyzed by a log-rank test. Because of the relatively small number of patients, it was deemed convenient to perform the statistical analyses by exact methods using the StatXact4 for Windows software package (Cytel Corporation, Cambridge, MA).
RESULTS

Relationship among Biological and Clinicopathological
Parameters. To confirm that receptor and ligand Fas expression were inversely correlated in BC, as we have recently reported (13), we analyzed the relationship between Fas and FasL in 167 stage-I/IIa-b patients included in this study. As summarized in Table 1 , the expression of receptor and ligand Fas antigens appeared to be significantly inversely related (P Ͻ 0.0001) with 69.0% of FasϪ cases expressing a FasLϩ phenotype and 70.8% of Fasϩ tumors displaying a FasLϪ phenotype. Double-negative (FasϪ/FasLϪ) and double-positive (Fasϩ/ FasLϩ) phenotypes accounted for 31.0% and 29.2% of the samples, respectively. Table 2 summarizes the correlation between the Fas/FasL immunoreactivity and the bio-pathological parameters. Both receptor and ligand were significantly related to tumor stage, the majority (73.5%) of stage I patients being Fas positive (P ϭ 0.01) and the majority (61%) of stage IIb patients FasL positive (P ϭ 0.04). Furthermore, FasL was associated to HER-2/neu overexpression (P ϭ 0.03). In contrast no correlation was found between Fas/FasL expression and menopausal status, nuclear grade or hormonal receptor status.
Impact of Biological Parameters on DFS and OS. The median length of follow-up of surviving patients was 69 months (range, 16 -97 months). The DFS and OS percentages were 72% (SE, Ϯ0.060) and 78% (SE, Ϯ0.036), respectively. Thirty-six deaths, due to cancer-related causes, and 46 recurrences, 3 of which were locoregional recurrences, 40 distant metastases, and 3 contralateral BC had occurred.
The results of the univariate and multivariate analyses for DFS and OS in the 167 patients included in the study are summarized in Tables 3 and 4 . Univariate analyses (Cox model) identified nuclear grade, tumor stage, lack of Fas expression, and FasL positivity as significant predictors of DFS and OS ( Table 3 ). All of the variables that significantly affected survival in the univariate analysis were introduced into Cox proportional risk model. As summarized in Table 4 , a backward step procedure indicated that stage IIb, lack of Fas staining, and FasL up-regulation, also adjusted for stage, were independent prognostic variables influencing both DFS and OS. Of interest, the relative risk of relapse and death associated with loss of the Fas receptor was particularly high, namely 8.5 (95% confidence interval, 4.40 -17.9; P Ͻ 0.0001) for DFS and 9.12 (95% confidence interval, 3.49 -23.82; P Ͻ 0.0001) for OS.
To obtain a better clinical understanding of the predictive value of response to adjuvant epirubicin-plus-cyclophosphamide treatment of these apoptosis-related molecules, we performed a Cox analysis using a four-category Fas/FasL phenotype (ϩ/Ϫ,ϩ/ϩ, Ϫ/ϩ, Ϫ/Ϫ) as a stratification factor both in the stage I-IIa and in the stage IIb groups of patients. As evidenced in Fig. 1 , a highly positive association between Fas/FasL phenotype and the cumulative hazard of relapse (Fig. 1A) as well as death (Fig. 1B) , was observed.
On the basis of these results, we also estimated the DFS and the 5-year survival rate for different combinations of the p-TNM stage and Fas/FasL covariates. Because of the relatively small number of events recorded in some of these subgroups, we estimated the statistical significance of our data by using the K sample log-rank exact test. As summarized in Table 5 
DISCUSSION
Despite aggressive adjuvant treatment, the appearance of metastatic spread is frequently seen during the clinical course of patients with BC. For this reason, knowledge of the processes underlying the inherent or acquired drug resistance of the tumor is a priority for modern biomedical research (17) .
Experimental evidence suggests that the deregulation of the mechanisms involved in the programmed cell death plays a relevant role in the progression of disease and the resistance to anticancer drugs (18) .
The clinical impact of apoptosis-related molecules such as p53 and bcl-2 has been extensively evaluated in the adjuvant setting of BC. However, conflicting results have been published concerning their involvement in resistance to cytotoxic drugs (19, 20) .
The Fas/FasL death pathway is another important mediator of apoptosis playing a pivotal role in the regulation of normal biological processes of breast glandular tissue modulating interaction between epithelial and nonepithelial cell populations (21) .
The new data presented herein demonstrate that the prognosis for patients with BC receiving adjuvant anthracyclinebased CT strongly depends on the Fas/FasL status. In particular, concomitant down-regulation of Fas and up-regulation of FasL expression seems to configure an aggressive tumor phenotype the biological behavior of which can be poorly modified by cytotoxic drugs.
Our findings are strongly supported by a number of in vitro studies that demonstrated that Adriamycin resistance in BC cell lines may be associated with a lack of Fas antigen expression and subsequent resistance to Fas-mediated cytotoxicity (22) .
In particular, it has been reported that the chemosensitivity of epithelial tumor cell lines to doxorubicin is strictly related to the activation of the Fas system. In fact, on doxorubicin treatment, strong induction of FasL and caspase activity were found in responsive, but not in unresponsive, tumor cells. Of interest, a down-regulation of Fas expression, together with a blockade of caspases activation, was found in resistant tumor cell lines (9, (25) established that the FasL:Fas ratio in tumor tissue is a strong prognostic factor in BC, and, more recently, an extended follow-up of that cohort of patients allowed them to investigate whether the FasL:Fas ratio may predict response to cytotoxic or hormonal therapies (26) . The data reported indicated that the FasL:Fas ratio may be useful not only as a prognostic factor but also as a predictive factor for projecting response to the antiestrogen tamoxifen. However, the FasL:Fas ratio had no significant predictive value in patients exclusively treated with CT. The lack of the predictive value of the FasL/Fas phenotype in these studies, apparently in contrast to our data, may be due to various reasons: different settings of patients; limited number of patients submitted to adjuvant CT (52 versus 167 in our study); different methods in evaluating Fas and FasL (IHC versus reverse transcription-PCR) with the possibility of analyzing residual normal glands and/or lymphocyte; and, last, the heterogeneity of the CT regimens.
Although functional data are lacking in this study, tumors displaying a Fasϩ/FasLϪ phenotype do seem to maintain an intact apoptotic pathway, thus becoming responsive to CT. On the contrary, BCs lacking Fas with FasL up-regulation experienced a particularly poor outcome. These findings can be related even to the role of FasL as a key effector molecule of T-cellmediated cytotoxicity against neoplastic cells (27) . In this context, our group recently reported (28) that Fasϩ/FasLϪ BC with tumor-infiltrating lymphocytes lacking Fas expression, presented a higher apoptotic index and a more favorable outcome than patients bearing FasϪ/FasLϩ BC and Fasϩ tumor-infiltrating lymphocytes.
These results, along with the recent observation that delivering a higher dosage of combination CT or adding newer compounds (e.g., taxanes) in the adjuvant setting failed to significantly improve BC outcome (29) , strongly support the belief that future therapeutic strategies should be directed at restoring the integrity of the apoptotic machinery.
In this context, our results are particularly relevant because the use of certain biological response modifiers, such as IFN-␥, may induce restoration of Fas-mediated apoptosis in cells lacking Fas expression (30, 31) .
To the best of our knowledge, this is the first study that has investigated the prognostic value of Fas system in a cohort of BC patients homogeneously treated with anthracycline-based CT. Nevertheless, because of the relatively small number of patients, our results should be regarded as preliminary. However, the prospective nature of patient enrollment and the homogeneous treatment assignment make our study in line with Hayes' recommendations (32) .
Hopefully the predictive value of Fas/FasL status will be confirmed in a large prospective study of adjuvant CT.
